Kiniksa [KNSA] vs Zoetis [ZTS] Detailed Stock Comparison

Kiniksa Pharmaceuticals, Ltd.

NASDAQ
Loading...

Zoetis Inc.

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Kiniksa Pharmaceuticals, Ltd. wins in 6 metrics, Zoetis Inc. wins in 14 metrics, with 0 ties. Zoetis Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Kiniksa Pharmaceuticals, Ltd. Zoetis Inc. Better
P/E Ratio (TTM) 57.39 19.58 Zoetis Inc.
Price-to-Book Ratio 5.78 15.04 Kiniksa Pharmaceuticals, Ltd.
Debt-to-Equity Ratio 1.67 279.59 Kiniksa Pharmaceuticals, Ltd.
PEG Ratio -0.22 2.81 Zoetis Inc.
EV/EBITDA 36.68 13.96 Zoetis Inc.
Profit Margin (TTM) 8.71% 28.24% Zoetis Inc.
Operating Margin (TTM) 9.78% 34.69% Zoetis Inc.
EBITDA Margin (TTM) 9.78% 34.69% Zoetis Inc.
Return on Equity 11.73% 65.99% Zoetis Inc.
Return on Assets (TTM) 7.18% 15.26% Zoetis Inc.
Free Cash Flow (TTM) $136.42M $2.28B Zoetis Inc.
Dividend Yield N/A 1.21% N/A
1-Year Return 76.83% -53.93% Kiniksa Pharmaceuticals, Ltd.
Price-to-Sales Ratio (TTM) 4.86 5.26 Kiniksa Pharmaceuticals, Ltd.
Enterprise Value $2.89B $56.75B Zoetis Inc.
EV/Revenue Ratio 4.27 6.00 Kiniksa Pharmaceuticals, Ltd.
Gross Profit Margin (TTM) 54.99% 70.17% Zoetis Inc.
Revenue per Share (TTM) $9 $21 Zoetis Inc.
Earnings per Share (Diluted) $0.75 $6.02 Zoetis Inc.
Beta (Stock Volatility) 0.06 0.97 Kiniksa Pharmaceuticals, Ltd.
Short % of Float 9.62% 4.06% Zoetis Inc.

Kiniksa Pharmaceuticals, Ltd. vs Zoetis Inc. Stock Performance Analysis

Loading Price Chart...

KNSA
ZTS

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Kiniksa Pharmaceuticals, Ltd.2.02%-11.22%-18.55%2.02%17.12%11.71%
Zoetis Inc.1.51%-4.46%-31.75%-39.76%-38.95%-38.30%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Kiniksa Pharmaceuticals, Ltd.76.83%231.14%262.67%149.25%149.25%149.25%
Zoetis Inc.-53.93%-54.80%-55.66%62.09%150.53%150.53%

Performance & Financial Health Analysis: Kiniksa Pharmaceuticals, Ltd. vs Zoetis Inc.

MetricKNSAZTS
Market Information
Market Cap i$3.29B$49.75B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i755,8512,727,710
90 Day Avg. Volume i660,0373,835,940
Last Close$47.87$167.10
52 Week Range$26.27 - $59.87$139.70 - $200.33
% from 52W High-20.04%-16.59%
All-Time High$59.87 (May 12, 2026)$249.27 (Dec 27, 2021)
% from All-Time High-20.04%-32.96%
Growth Metrics
Quarterly Revenue Growth0.65%0.03%
Quarterly Earnings Growth0.65%0.04%
Financial Health
Profit Margin (TTM) i0.09%0.28%
Operating Margin (TTM) i0.10%0.35%
Return on Equity (TTM) i0.12%0.66%
Debt to Equity (MRQ) i1.67279.59
Cash & Liquidity
Book Value per Share (MRQ)$7.44$7.84
Cash per Share (MRQ)$5.41$5.48
Operating Cash Flow (TTM) i$137.98M$2.90B
Levered Free Cash Flow (TTM) i$97.89M$1.79B
Dividends
Last 12-Month Dividend Yield iN/A1.21%
Last 12-Month Dividend iN/A$2.03

Valuation & Enterprise Metrics Analysis: Kiniksa Pharmaceuticals, Ltd. vs Zoetis Inc.

MetricKNSA (Apr 24, 2026)ZTS (Apr 13, 2026)
Price Ratios
P/E Ratio (TTM) i57.3919.58
Forward P/E i29.1515.61
PEG Ratio i-0.222.81
Price to Sales (TTM) i4.865.26
Price to Book (MRQ) i5.7815.04
Market Capitalization
Market Capitalization i$3.29B$49.75B
Enterprise Value i$2.89B$56.75B
Enterprise Value Metrics
Enterprise to Revenue i4.276.00
Enterprise to EBITDA i36.6813.96
Risk & Other Metrics
Beta i0.060.97
Book Value per Share (MRQ) i$7.44$7.84

Financial Statements Comparison: Kiniksa Pharmaceuticals, Ltd. vs Zoetis Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricKNSA (2025)ZTS (2025)
Revenue/Sales i677.56M9.47B
Cost of Goods Sold i307.22M2.67B
COGS % of Revenue i45.3%28.2%
Gross Profit i370.35M6.80B
Gross Margin i54.7%71.8%
Research & Development i96.85M698.00M
Operating Income (EBIT) i77.22M3.60B
Operating Margin i11.4%38.0%
EBITDA i78.78M4.17B
EBITDA Margin i11.6%44.1%
Pre-Tax Income i88.87M3.36B
Pre-Tax Income % of Revenue i13.1%35.5%
Income Tax i29.86M687.00M
Income Tax % of Revenue i4.4%7.3%
Net Income (Profit) i59.01M2.67B
Profit Margin i8.7%28.2%

Balance Sheet & Liquidity Metrics

MetricKNSA (2025)ZTS (2025)
Cash & Equivalents i165.60M2.31B
Total Current Assets i527.18M6.77B
Total Current Assets % of Revenue i77.8%71.5%
Total Current Liabilities i139.18M2.24B
Total Current Liabilities % of Revenue i20.5%23.6%
Long-Term Debt i6.51M9.24B
Long-Term Debt % of Revenue i1.0%97.6%
Total Shareholders Equity i567.61M3.33B
Retained Earnings i-462.14M13.74B
Retained Earnings % of Revenue i-68.2%145.2%
Property, Plant & Equipment i13.81M288.00M

Cash Flow Statement Comparison

MetricKNSA (2025)ZTS (2025)
Operating Cash Flow i124.01M2.78B
Operating Cash Flow % of Revenue i18.3%29.3%
Capital Expenditures i-1.57MN/A
Free Cash Flow i136.42M2.28B
FCF Margin i20.1%24.1%
Debt Repayment iN/A-1.35B
Common Stock Repurchase i-7.73M-3.24B

Short Interest & Institutional Ownership Analysis

MetricKNSAZTS
Shares Short i4.09M15.12M
Short Ratio i6.093.60
Short % of Float i9.62%4.06%
Shares Outstanding i76.29M424.93M
Float Shares i39.90M421.29M
% Held by Insiders i3.58%0.15%
% Held by Institutions i103.89%101.50%
% Held by Public i-7.47%-1.65%

Dividend Analysis & Yield Comparison: Kiniksa Pharmaceuticals, Ltd. vs Zoetis Inc.

MetricKNSAZTS
Last 12-Month Dividend iN/A$2.03
Last 12-Month Dividend Yield iN/A1.21%
3-Year Avg Annual Dividend iN/A$1.80
3-Year Avg Dividend Yield iN/A0.29%
3-Year Total Dividends iN/A$5.39
Ex-Dividend DateN/AJan 20, 2026